Complete Tumor Regression by Liposomal Bortezomib in a Humanized Mouse Model of Multiple Myeloma
Main Authors: | Anil K. Deshantri, Marcel H.A.M. Fens, Ruud W.J. Ruiter, Josbert M. Metselaar, Gert Storm, Sanjay N. Mandhane, Gerard H.M. Graat, Eef G.W. Lentjes, Huipin Yuan, Joost D. de Bruijn, Tuna Mutis, Anton C.M. Martens, Richard W.J. Groen, Raymond M. Schiffelers |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-10-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000463 |
Similar Items
-
Development and characterization of liposomal formulation of bortezomib
by: Anil K. Deshantri, et al.
Published: (2019-12-01) -
Polymeric micelles loaded with carfilzomib increase tolerability in a humanized bone marrow-like scaffold mouse model
by: Aida Varela-Moreira, et al.
Published: (2020-12-01) -
Liposome-Encapsulated Prednisolone Phosphate Inhibits Growth of Established Tumors in Mice
by: Raymond M. Schiffelers, et al.
Published: (2005-02-01) -
Changes in circulating endothelial progenitor cells predict responses of multiple myeloma patients to treatment with bortezomib and dexamethasone
by: L. Wang, et al.
Published: (2015-06-01) -
Changes in circulating endothelial progenitor cells predict responses of multiple myeloma patients to treatment with bortezomib and dexamethasone
by: L. Wang, et al.
Published: (2015-08-01)